668477-50-7

Upstream product

• 620-17-7 3-ethylphenol 
• 100-44-7 benzyl chloride 
• 173098-21-0 1-Ethenyl-3-(phenylmethoxy)benzene 
• 128133-59-5 1-ethynyl-3-(phenylmethoxy)benzene 
• 107623-21-2 1-(benzyloxy)-3-iodobenzene 

Downstream Products

• 668477-52-9 4-benzyloxy-2-ethyl-benzaldehyde 
• 668477-51-8 4-(benzyloxy)-1-bromo-2-ethylbenzene 
• 729590-49-2 4-bromo-3-propylbenzyloxybenzene 

Relevant academic research and scientific papers

Iron-catalysed alkene hydrogenation and reductive cross-coupling using a bench-stable iron(II) pre-catalyst

Operationally simple, iron-catalysed hydrogenation and reductive cross-coupling protocols have been developed using a bench-stable iron(ii) pre-catalyst. The hydrogenation of 18 alkenes (50-99%) and reductive cross-coupling of vinyl halides with aryl- and alkyl Grignard reagents (8 examples, 18-99%) is reported using 3 mol% pre-catalyst and hydrogen as stoichiometric reductant (1-50 bar).

Facile regio- and stereoselective hydrometalation of alkynes with a combination of carboxylic acids and group 10 transition metal complexes: Selective hydrogenation of alkynes with formic acid

A facile, highly stereo- and regioselective hydrometalation of alkynes generating alkenylmetal complex is disclosed for the first time from a reaction of alkyne, carboxylic acid, and a zerovalent group 10 transition metal complex M(PEt3)4 (M = Ni, Pd, Pt). A mechanistic study showed that the hydrometalation does not proceed via the reaction of alkyne with a hydridometal generated by the protonation of a carboxylic acid with Pt(PEt 3)4, but proceeds via a reaction of an alkyne coordinate metal complex with the acid. This finding clarifies the long proposed reaction mechanism that operates via the generation of an alkenylpalladium intermediate and subsequent transformation of this complex in a variety of reactions catalyzed by a combination of Bronsted acid and Pd(0) complex. This finding also leads to the disclosure of an unprecedented reduction of alkynes with formic acid that can selectively produce cis-, trans-alkenes and alkanes by slightly tuning the conditions.

5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.